This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
In the article the authors examine the April 2 Executive Order signed by President Trump highlighting US trading partners’ nontariff barriers, such as...
Competitive rare diseases: Setting the scene In the first installment of a new series on competitive categories in rare diseases, CRA Life Sciences’s Bhavesh...
CRA is a proud sponsor of the epicenter of the specialty pharmacy industry event. Becky Davis presents the session titled “GLP-1s: Riding the Wave of...
Hannah Armstrong moderates the session titled “Addressing Challenges with Access to Fertility Treatment and Preservation in APAC: Policy Recommendations for...
